Literature DB >> 20146947

[COPD routine management in France: are guidelines used in clinical practice?].

G Jebrak1.   

Abstract

INTRODUCTION: COPD management guidelines have been proposed to improve the major outcomes for COPD patients. In clinical practice, COPD treatment is only partially consistent with current guidelines and recommendations.
OBJECTIVE: Global initiative for chronic obstructive lung disease (GOLD) guidelines are based on a COPD severity scale and are subject to change as the evidence based evolves. The main purpose of our study was to access whether the treatments prescribed to patients with COPD were consistent with these guidelines.
METHODS: Treatments prescribed by French physicians to 542 patients with COPD in stable conditions were recorded according to the severity of obstruction, using GOLD classification. We compared our prescription data base with the GOLD guidelines.
RESULTS: Forty percent of the initial physicians were chest specialists. PATIENTS: 78.3 % men, (64.8+/-10.8years) and 25 % were still smokers at inclusion. We found an important discrepancy between recommended treatment and COPD severity. Bronchodilators were commonly prescribed, but 11 % in severe COPD (stages III and IV) did not receive them. Inhaled steroids (ICS) were used respectively in 55.2 %, 59.4 % of patients in stages I, II (FEV1>50 %) (for whom they are not recommended) and 77.4 and 85.3 % in stages III and IV. Only 30 % of patients used ICS+beta2 agonists in the same device. Influenza vaccination had been performed in only half of patients whatever the severity of COPD. Pulmonary rehabilitation had been used by 10 % of patients, (stage II: 6.4 %, stage III: 9.6 %, stage IV: 20.6 %).
CONCLUSIONS: We confirmed that there are discrepancies between COPD guidelines and routine treatments. Some treatments such as ICS were overused in mild phenotypes, whereas in a high proportion of cases influenza immunisation and rehabilitation were omitted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20146947     DOI: 10.1016/j.rmr.2009.08.002

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  15 in total

1.  Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily Activities.

Authors:  Donald A Mahler; Dorothy L Keininger; Karen Mezzi; Robert Fogel; Donal Banerji
Journal:  Chronic Obstr Pulm Dis       Date:  2016-09-09

2.  Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis.

Authors:  Rob W Flynn; Thomas M MacDonald; Adrian Hapca; Isla S MacKenzie; Stuart Schembri
Journal:  Respir Res       Date:  2014-11-19

3.  Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD.

Authors:  Dirkje S Postma; Nicolas Roche; Gene Colice; Elliot Israel; Richard J Martin; Willem Mc van Aalderen; Jonathan Grigg; Anne Burden; Elizabeth V Hillyer; Julie von Ziegenweidt; Gokul Gopalan; David Price
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-10-17

Review 4.  Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm.

Authors:  Morven Wilkie; Simon Finch; Stuart Schembri
Journal:  COPD       Date:  2015-03-16       Impact factor: 2.409

5.  First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.

Authors:  David Price; Marc Miravitlles; Ian Pavord; Mike Thomas; Jadwiga Wedzicha; John Haughney; Katsiaryna Bichel; Daniel West
Journal:  NPJ Prim Care Respir Med       Date:  2016-11-03       Impact factor: 2.871

6.  Adherence to the GOLD Guideline in COPD Management of South Korea: Findings from KOCOSS Study 2011-2018.

Authors:  Tae-Ok Kim; Hong-Joon Shin; Yu-Il Kim; Chin-Kook Rhee; Won-Yeon Lee; Seong-Yong Lim; Seung-Won Ra; Ki-Suck Jung; Kwang-Ha Yoo; Seoung-Ju Park; Sung-Chul Lim
Journal:  Chonnam Med J       Date:  2019-01-25

7.  Multidimensional analyses to assess the relations between treatment choices by physicians and patients' characteristics: the example of COPD.

Authors:  Nicolas Roche; Christos Chouaid; Bertrand Delclaux; Yan Martinat; Jean-Michel Marcos; Hervé Pégliasco; Bruno Scherrer
Journal:  BMC Pulm Med       Date:  2012-08-06       Impact factor: 3.317

8.  Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.

Authors:  David Price; Daniel West; Guy Brusselle; Kevin Gruffydd-Jones; Rupert Jones; Marc Miravitlles; Andrea Rossi; Catherine Hutton; Valerie L Ashton; Rebecca Stewart; Katsiaryna Bichel
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-08-27

Review 9.  Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal.

Authors:  Barbara P Yawn; Samy Suissa; Andrea Rossi
Journal:  NPJ Prim Care Respir Med       Date:  2016-09-29       Impact factor: 2.871

10.  Overtreatment of COPD with inhaled corticosteroids--implications for safety and costs: cross-sectional observational study.

Authors:  Patrick White; Hannah Thornton; Hilary Pinnock; Sofia Georgopoulou; Helen P Booth
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.